– Global, pivotal Phase 3 study will evaluate efficacy and safety of zorevunersen compared to sham over a 52-week treatment…
Innovating for the Public Good Reveals the Red Tape Barriers to Social Safety Net Programs,Increased by One Big Beautiful Bill…
RADIANT study with vormatrigine in focal onset seizure (FOS) patients over eight weeks demonstrated 56.3% median reduction in seizure frequency…
Reports second quarter revenues of $0.1 billion, GAAP net loss of $(0.8) billion and GAAP EPS of $(2.13)Updates 2025 projected…
SPRINGFIELD, Mo., July 30, 2025 /PRNewswire/ -- Hearo Technologies and Smart Living Systems (SLS), the technology innovation arm of LADD, Inc.,…
Aliso Viejo, CA, July 30, 2025 (GLOBE NEWSWIRE) -- Life Backup Plan by Galacxia, Inc, redefining how individuals and care…
Data readout expected in Q1 2026MIAMI, July 29, 2025 (GLOBE NEWSWIRE) -- Vivex Biologics, Inc., a leader in developing and…
The Phase 3 clinical trial of sovateltide, RESPECT-ETB, is expected to enroll over 500 patients with a primary endpoint of…
Nes-Ziona, Israel, July 28, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy…
– ATH434 Demonstrated Clinical Benefit on the Unified MSA Rating Scale and Global Measures of Neurological Symptoms – – Neuroimaging…